Accessibility
Language
Rethinking personalized oncology: PGXperts strengthens individual therapy choice with the CAREOMICS project
07.07.2025
Every year, around 500,000 people in Germany are diagnosed with cancer for the first time. It has long been known that not every therapy is equally effective for every patient. Individual genetic characteristics play a key role in how well a treatment works and what side effects may occur. The new CAREOMICS (Comprehensive Approach on Radio- and Pharmacogenomics in Oncological Decision Support) project from PGXperts addresses precisely this issue and pursues an innovative, data-driven approach in personalized oncology. The company is thus taking a new step towards individualized treatment.
From diagnosis to individual therapy
CAREOMICS brings together three strong partners: the Department of Radiation Oncology and Radiotherapy at the TUM Klinikum rechts der Isar in Munich, the Institute of Human Genetics at the University Hospital Bonn and PGXperts GmbH, which is coordinating the project and developing an AI-supported decision support system.
The aim is to make it easier for doctors to select the best possible initial treatment for each patient.
The basis for this is genetic information and two special types of data:
Firstly, radiogenomic (RGx) data, which shows how genetic characteristics influence the response to radiotherapy.
Secondly, pharmacogenetic (PGx) data, which provides information on how drugs work and are tolerated in the body.
This allows treatment to be tailored precisely, effectively and individually.
Two central building blocks for more successful treatment
At the heart of the project are two pioneering approaches that are set to revolutionize personalized cancer treatment. Firstly, genetic testing specially developed by PGXperts makes it possible to identify patients who may be particularly sensitive to certain therapies as early as the cancer diagnosis stage. A specially designed onco-software evaluates the genetic data and offers doctors a reliable, scientifically sound decision-making tool. On the other hand, CAREOMICS uses artificial intelligence to learn from the experience of past therapies. The continuous analysis of treatment data makes it possible to tailor treatment recommendations to patient groups for whom they are particularly effective.
Funding and future prospects
The CAREOMICS project, funded by the Federal Ministry of Research, Technology and Space (BMFTR), has a total volume of 1.89 million euros, of which 1.42 million euros are allocated to the funding measure "Optimal therapies through data-driven decision-making and support systems". The project will run for 2.5 years.
With CAREOMICS, PGXperts is part of an important milestone in personalized cancer therapy. The combination of state-of-the-art genetic diagnostics with intelligent data analysis opens up new perspectives for a more precise and effective choice of therapy. In this dynamic environment, Bayern Innovativ supports the exchange between science, clinics and industry as an established partner - and thus contributes to bringing innovative healthcare solutions into practice. CAREOMICS is an important boost for Bavaria as a location for innovation: the project not only strengthens regional research and medical care, but also underlines Bavaria's leading role in the development of digital healthcare solutions. At the same time, it shows how targeted funding and clever networking can make Bavaria a competitive and attractive healthcare location in the long term. Bayern Innovativ plays a key role as a mediator between stakeholders and as a driver for sustainable medical innovations in Bavaria. With the combined forces of research, clinics and technology, CAREOMICS is shaping the personalized medicine of tomorrow.
